Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4

  • Bioorg Med Chem Lett. 2014 Jul 1;24(13):2885-91. doi: 10.1016/j.bmcl.2014.04.089.
Yingcai Wang  1 Richard Connors  2 Pingchen Fan  2 Xiaodong Wang  2 Zhongyu Wang  2 Jiwen Liu  2 Frank Kayser  2 Julio C Medina  2 Sheree Johnstone  2 Haoda Xu  2 Stephen Thibault  2 Nigel Walker  2 Marion Conn  3 Ying Zhang  3 Qingxiang Liu  3 Mark P Grillo  4 Alykhan Motani  3 Peter Coward  3 Zhulun Wang  5
Affiliations
  • 1. Department of Therapeutic Discovery, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA. Electronic address: [email protected].
  • 2. Department of Therapeutic Discovery, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA.
  • 3. Department of Metabolic Disorders, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA.
  • 4. Department of Pharmacokinetics & Drug Metabolism, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA.
  • 5. Department of Therapeutic Discovery, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA. Electronic address: [email protected].
Abstract

Retinol-Binding Protein 4 (RBP4) is a plasma protein that transports retinol (vitamin A) from the liver to peripheral tissues. This Letter highlights our efforts in discovering the first, to our knowledge, non-retinoid small molecules that bind to RBP4 at the retinol site and reduce serum RBP4 levels in mice, by disrupting the interaction between RBP4 and transthyretin (TTR), a plasma protein that binds RBP4 and protects it from renal excretion. Potent compounds were discovered and optimized quickly from high-throughput screen (HTS) hits utilizing a structure-based approach. Inhibitor co-crystal X-ray structures revealed unique disruptions of RBP4-TTR interactions by our compounds through induced loop conformational changes instead of steric hindrance exemplified by fenretinide. When administered to mice, A1120, a representative compound in the series, showed concentration-dependent retinol and RBP4 lowering.

Keywords
A1120; Fenretinide; Non-retinoid; RBP4; Small molecules.
Products